Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Authors:
Top Cited Papers
Open Access
- 1 April 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (10) , 1180-1187
Abstract
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a protocol-defined wait-and-see subset analysis of eligible patients where treatment resumption with larotrectinib was allowed if disease progressed. We also assessed the safety and efficacy of larotrectinib in all pediatric patients with sarcoma. This cohort included 91 patients (younger than 18 years) from two clinical trials: infantile fibrosarcoma (49), other soft tissue sarcomas or related mesenchymal tumors (41), and bone sarcoma (1). Treatment-related adverse events were of maximum grade 1 or 2 in 25% and 25% of patients, respectively. The overall response rate was 87% (95% CI, 78 to 93). In the wait-and-see analysis, 47 patients discontinued larotrectinib. Median time from discontinuation to disease progression was not reached. Sixteen patients had tumor progression during the wait-and-see period. All 16 patients resumed larotrectinib, and 15 (94%) achieved disease control, with 11 objective responses. Larotrectinib continues to demonstrate durable responses with favorable safety in children with TRK fusion sarcomas. Treatment discontinuation is feasible in select patients with objective response and clinical benefit noted in those who have disease progression after elective treatment discontinuation.Keywords
This publication has 14 references indexed in Scilit:
- Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)ESMO Open, 2024
- Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysisExpert Review of Anticancer Therapy, 2023
- Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversiesEuropean Journal of Cancer, 2020
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsThe Lancet Oncology, 2020
- TRK inhibitors in TRK fusion-positive cancersAnnals of Oncology, 2019
- Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancerAnnals of Oncology, 2019
- NTRK fusion-positive cancers and TRK inhibitor therapyNature Reviews Clinical Oncology, 2018
- The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomasCancer, 2018
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 studyThe Lancet Oncology, 2018
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenNew England Journal of Medicine, 2018